Qilian International Holding Group (Qilian International Holding Group) ROCE % : -10.94% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Qilian International Holding Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Qilian International Holding Group's annualized ROCE % for the quarter that ended in Sep. 2023 was -10.94%.

Qilian International Holding Group ROCE % Historical Data

The historical data trend for Qilian International Holding Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qilian International Holding Group ROCE % Chart

Qilian International Holding Group Annual Data

Trend

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROCE %

Get a 7-Day Free Trial

33.59

22.68

6.79

4.47

-4.84

Qilian International Holding Group Semi-Annual Data
	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
ROCE %	Get a 7-Day Free Trial								1.23	4.47	4.34	1.11	-10.94

Qilian International Holding Group ROCE % Calculation

Qilian International Holding Group's annualized ROCE % for the fiscal year that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2023 )		(A: Sep. 2022 )		(A: Sep. 2023 )
	=	-2.418	/	( ( (64.527 - 9.181)	+	(51.258 - 6.66) )	/ 2 )
	=	-2.418	/	( (55.346	+	44.598)	/ 2 )
	=	-2.418	/	49.972
	=	-4.84 %

Qilian International Holding Group's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Mar. 2023 )		(Q: Sep. 2023 )
	=	-5.45	/	( ( (64.234 - 9.183)	+	(51.258 - 6.66) )	/ 2 )
	=	-5.45	/	( ( 55.051	+	44.598 )	/ 2 )
	=	-5.45	/	49.8245
	=	-10.94 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2023) EBIT data.

Qilian International Holding Group (NAS:QLI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Qilian International Holding Group ROCE % Related Terms

Thank you for viewing the detailed overview of Qilian International Holding Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Qilian International Holding Group (Qilian International Holding Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Qilian International Holding Group Ltd (NAS:QLI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jiuquan Economic and Technological Development Zone, Gansu Province, Jiuquan, CHN, 735000

Website

http://ir.qlsyy.net

Qilian International Holding Group Ltd is a pharmaceutical and chemical company. The company is engaged in the development, manufacture, marketing, and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers. It operates through three segments namely, Oxytetracycline and Licorice products and TCMD; Fertilizer; and Heparin products and Sausage casing. Oxytetracycline and Licorice products and TCMD segment generates majority of the revenue.